摘要
蛋白酶主要是单核细胞和淋巴细胞中表达,负责细胞免疫的抗原肽的生成。在曝光于细胞炎症因子IFN-γ和TNF-ααγ下时,构成亚基可以被免疫核心颗粒β1i, β2i和 β5i取代。最近的研究表明,免疫蛋白酶体功能不仅限于MHC I类分子的表达,它还与许多病理疾病如血液系统恶性肿瘤、炎症和自身免疫性疾病有关。目前市售的蛋白酶体抑制剂Bortezomib 和Carfilzomib,已在多发性骨髓瘤和其他疾病中证明有效,它以免疫本构模型和免疫蛋白酶体紊乱为靶点。特异性的缺乏解释了这些药物的副作用,相反,通过选择性地靶向免疫蛋白酶体,它可能会使抗血管生成和抗淋巴瘤疗效不变,同时提高药物的治疗指数。本文旨在讨论最近几年发展起来的最有前景的免疫蛋白酶体核心颗粒的选择性抑制剂, 并主要关注于其结构特点、作用机制及治疗应用。
关键词: 免疫蛋白酶体,核心颗粒,免疫蛋白酶体的选择性抑制剂,血液系统恶性肿瘤、自身免疫性疾病、炎症性疾病。
Current Medicinal Chemistry
Title:Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Volume: 23 Issue: 12
Author(s): Roberta Ettari, Santo Previti, Alessandra Bitto, Silvana Grasso, Maria Zappalà
Affiliation:
关键词: 免疫蛋白酶体,核心颗粒,免疫蛋白酶体的选择性抑制剂,血液系统恶性肿瘤、自身免疫性疾病、炎症性疾病。
摘要: The immunoproteasome is predominantly expressed in monocytes and lymphocytes and is responsible for the generation of antigenic peptides for cell-mediated immunity. Upon the exposure of inflammatory cytokines IFN-γ and TNF-α, constitutive subunits can be replaced by the synthesis of the immuno-core particles β1i, β2i and β5i. Recent studies demonstrated that the immunoproteasome function is not only limited to MHC class I presentation, but it is also implicated in a number of pathological disorders including hematological malignancies, inflammatory and autoimmune diseases. At present the commercially available proteasome inhibitors Bortezomib and Carfilzomib, which have been validated in multiple myeloma and other diseases, appear to target both the constitutive and immunoproteasomes indiscriminately. This lack of specificity may, in part, explain some of the side effects of these agents. In contrast, by selectively targeting the immunoproteasome, it may be possible to keep the antimyeloma and antilymphoma efficacy unchanged and, at the same time, to increase the therapeutic index. The aim of this review article is to discuss the most promising immunoproteasome core particle-selective inhibitors which have been developed in the recent years, with a particular attention to their structural features, mechanism of action and therapeutic application.
Export Options
About this article
Cite this article as:
Roberta Ettari, Santo Previti, Alessandra Bitto, Silvana Grasso, Maria Zappalà , Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases, Current Medicinal Chemistry 2016; 23 (12) . https://dx.doi.org/10.2174/0929867323666160318173706
DOI https://dx.doi.org/10.2174/0929867323666160318173706 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Fundamental Concepts of the Angiogenic Process
Current Molecular Medicine Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation
Current Pharmaceutical Design Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers
Current Drug Targets Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Obesity: An Emerging Importance of Progenitors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design STIP Regulates ERK1/2 Signaling Pathway Involved in Interaction with PP1γ in Lymphoblastic Leukemia
Current Molecular Medicine Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Apoptosis Inducing Effects of Thymus Linearis Methanolic Extract in HCT-116 Cells and LC-MS Chemical Profiling of Its Active Constituents
The Natural Products Journal